Novel agents such as the BTK inhibitor ibrutinib are an excellent addition to the arsenal of treatments against chronic lymphocytic leukemia (CLL); however, patients eventually become refractory. Stephan Stilgenbauer, MD, of the University of Ulm, Ulm, Germany, discusses the investigation of the next-generation BTK inhibitor vecabrutinib, which as a competitive inhibitor should avoid this mechanism of resistance. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.